6 November 2026
European Medicines Agency: Meeting Highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 November 2026
The European Medicines Agency’s (EMA) Committee for Veterinary Medicinal Products (CVMP) has adopted positive opinions for several new veterinary medicines. Notably, the Committee recommended the authorisation of Scovella (velagliflozin) for horses with Equine Metabolic Syndrome, the first veterinary medicinal product recommended under the EU’s limited market regulatory framework introduced by Regulation (EU) 2019/6. Positive opinions were also adopted for Credelio Quattro for parasitic infections in dogs, Laverdia for lymphoma in dogs, Streptoporc for immunisation against Streptococcus suis in pigs, and Nobivac PLUS DHPPi / Leptos for immunisation of dogs. The CVMP also adopted several variations to existing authorisations and advanced work on veterinary pharmacovigilance, antimicrobial resistance and international regulatory harmonisation.
For more information, see here.